Agilent Technologies Acquires ACEA Biosciences to Strengthen Platform and Capabilities in Cell Analysis
Shots:
- ACEA to receive $250M in upfront cash as a total deal value- adding a differentiated portfolio and organizational capabilities in cell analysis
- Agilent will get hold of ACEA’s CFDA and CE-IVD labelled cytometer configuration- i.e. NovoCyte flow cytometer and xCELLigence Real-Time Cell analyzer used for monitoring growth- function- and cellular responses of cells
- The acquisition will expand Agilent’s R&D- manufacturing & operations- and commercial capabilities and coverage in China
Ref: Agilent Technologies | Image: Pr web
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com